Aurobindo Pharma Ltd proposes to transfer its domestic branded generic formulations business to its wholly owned subsidiary, Auropharm Ltd, through a slump sale on a going concern basis for a consideration of ₹143.21 crore. The transaction will include the transfer of all related assets and liabilities associated with the business. Alignment with group’s consolidation strategy […]